8月19日，福泰制药盘中上涨3.04%，报543.95美元/股，成交额1.24亿美元。消息面上，RBC Capital近期发布研报指出，公司拥有多个潜在管线催化剂，整体风险收益比偏正面，其中VX-828囊性纤维化一期数据及povetacicept的IgA肾病适应症审批（PDUFA日期为11月30日）均为关键节点。
此外，竞争对手囊性纤维化药物研发未达预期，进一步巩固了公司在该领域的主导地位。基本面方面，公司二季度营收33.34亿美元超市场预期，全年收入指引上调至131亿至132亿美元。多家机构维持买入评级，高盛目标价652美元、Jefferies目标价610美元，均显著高于当前股价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.